Product category |
|
Therapeutic indication |
- Use in combination with chloroquine for the prevention of relapse of P. vivax malaria from 16 years of age
|
Dosing |
|
Efficacy |
|
Key features |
|
Challenges |
|
Status |
- Approved by US FDA July 2018 and by Australian TGA September 2018
- Approved in first malaria-endemic country (Brazil) in October 2019, in Thailand in December 2019 and in Peru in January 2021
- TRust feasability study in Brazil initiated
- Under review in six endemic countries including two following subsequent ASEAN joint assessment procedure review
|
Next milestone |
Pharmacokinetic results expected for the INSPECTOR study, assessing safety and efficacy of TQ in combination with DHA-PQP by end of Q3 2022 Second interim analysis from the TRuST feasibility study in Brazil expected by end Q3 2022; start of ARCTIC feasibility study in Thailand, in conjunction with quantitative G6PD testing expected in Q2 2022
|
MMV Project Director |
|